



7.28 05

1/10/05

PATENT
Docket No. 375462-002US
EXPRESS MAIL NO. EL 989614126 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: ROSSI Art Unit: 1632
Serial No.: 10/053,355 Examiner: LI, Qian Janice
Date Filed: November 8, 2001 Confirmation No.: 5867
Title: PRODUCTION OF CULTURED HUMAN MAST CELLS AND
BASOPHILS FOR HIGH THROUGHPUT SMALL MOLECULE DRUG
DISCOVERY

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 CFR §§ 1.97 and 1.98, Applicant submits herewith patents, publications and/or other information (listed below and/or on the attached Substitute Form PTO 1449) that may be material to the examination of the captioned application, and in respect of which there may be a duty of disclosure as set forth in 37 CFR § 1.56, for consideration and to be made of record in the captioned application by the U.S. Patent and Trademark Office.

In accordance with 37 CFR 1.98:

☒ (a)(2), copies of the documents listed on the attached Substitute Form PTO 1449 are enclosed herewith;

☐ (d), copies of the documents listed on the attached Substitute Form PTO 1449 are not enclosed herewith, because the information was previously submitted to, or cited by, the U.S. Patent and Trademark Office in application Serial No. _____, of which the captioned application claims benefit under 35 U.S.C. § 120, and the Information Disclosure Statement submitted in this parent application complied with paragraphs (a) through (c) of 37 CFR § 1.98 or

☐ (e), copies of U.S. patents and published U.S. applications listed on the attached Substitute Form PTO 1449 are not required and are therefore not enclosed because this Information Disclosure Statement is being submitted in compliance with the Office's electronic filing system.

☐ In accordance with 37 CFR § 1.97(b), this Information Disclosure Statement is being submitted:

☐ (1) Within three months of the filing date of a national application other than a continued prosecution application under 37 CFR § 1.53(d);

☐ (2) Within three months of the of entry of the national stage as set forth in 37 CFR § 1.491 in an international application;

☐ (3) Before the mailing of a first Office Action on the merits; or

☐ (4) Before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR § 1.114.

☒ In accordance with 37 CFR § 1.97(c), this Information Disclosure Statement is being submitted after one of the time periods specified by CFR § 1.97(b), but before the mailing date of any of a final Office Action under 37 CFR § 1.113, a notice of allowance under 37 CFR § 1.113, or an action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ (1) The statement specified in 37 CFR § 1.98(e); or

☒ (2) The fee set forth in 37 CFR § 1.17(p).

☐ In accordance with 37 CFR § 1.97(d), this Information Disclosure Statement is being submitted after one of the time periods specified by CFR § 1.97(c), but on or before payment of the issue fee, and is accompanied by:

☐ (1) The statement specified in 37 CFR § 1.97(e); and

☐ (2) The fee set forth in 37 CFR § 1.17(p).

☐ Pursuant to 37 CFR § 1.97(e), the undersigned hereby states that:

☐ (1) Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or

☐ (2) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making a reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 CFR § 156(c) more than three months prior to the filing of this Information Disclosure Statement.

As specified in 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that no other material information as defined in 37 CFR § 1.56(a) exists.

As specified in 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any information cited therein is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

Moreover, while the patents, publications and/or other information disclosed in this Information Disclosure Statement may be “material” pursuant to 37 CFR § 1.56, the Disclosure is not intended to constitute an admission that any patents, publications and/or other information included referred to therein is “prior art” to the captioned application unless specifically designated as such.


☐ No fees are believed due in connection with this Information Disclosure Statement. However, the Patent Office is authorized to take any fee(s) that may be required, or credit any overpayment(s), to Dechert LLP Deposit Account No. 50-2778 (Order No.: _____)

☒ The fee specified in 37 CFR § 1.17(p) are believed due in connection with this Information Disclosure Statement. The Patent Office is authorized to take this fee, and any other

fee that may be required in connection with this Information Disclosure Statement, or credit any overpayment, to Dechert LLP Deposit Account No. 50-2778 (Order No. 375462-002US).

It is respectfully submitted that this Information Disclosure Statement is in compliance with 37 CFR § 1.98 and MPEP § 609. Accordingly, consideration of the foregoing and prompt return of a copy of the enclosed Substitute form PTO 1449 with the Examiner's initials in the left column in accordance with MPEP § 609 are respectfully requested.

Respectfully submitted,



Euk Y. Oh, Reg. No. 54,345 for
Ann M. Caviani Pease, Reg. No. 42,067

Dated: July 27, 2005

Customer No.: 37509

DECHERT LLP

P.O. Box 10004

Palo Alto, CA 94303-0961

Telephone: (650) 813-4800

Facsimile: (650) 813-4848



PATENT
Docket No. 375462-002US
EXPRESS MAIL NO. EL 989614126 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: ROSSI Art Unit: 1632
Serial No.: 10/053,355 Examiner: LI, Qian Janice
Date Filed: November 8, 2001 Confirmation No.: 5867
Title: PRODUCTION OF CULTURED HUMAN MAST CELLS AND
BASOPHILS FOR HIGH THROUGHPUT SMALL MOLECULE DRUG
DISCOVERY

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450


SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Sir:

Enclosed are the following documents for filing in the above-referenced patent application:

- ☒ Supplemental Information Disclosure Statement
- ☒ Substitute Form 1449
- ☒ Copy of International/Foreign Search Report
- ☒ Copies of References (5 references/ 2 copies each)
- ☒ Return Receipt Postcard

No fees beyond those included with this submission are due. However, the Commissioner is authorized to charge any deficiencies, or credit any overpayment to Dechert LLP Deposit Account No. 50-2778 (Order No.: 375462-002US).



EXPRESS MAIL NO. EL 989614126 US

Please direct any inquiries in connection with the above referenced application to the undersigned at telephone number (415) 262-4504.

Respectfully submitted,

Dated: July 27, 2005

Euk Y. Oh, Reg. No. 54,345 for
Ann M. Caviani Pease, Reg. No. 42,067

Customer No.: 37509


DECHERT LLP

P.O. Box 10004

Palo Alto, CA 94303-0961

Telephone: (650) 813-4800

Facsimile: (650) 813-4848



Substitute for form 1449A/PTO
(Modified)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/053,355
Filing Date	November 8, 2001
First Named Inventor	Alexander B. ROSSI
Art Unit	1632
Examiner Name	LI, Qian Janice
Attorney Docket Number	375462-002US

Sheet	1	of	1
-------	---	----	---

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	US-4,559,310 A	12-17-1985	CANTOR et al.	
	A2	US-			
	A3	US-			
	A4	US-			
	A5	US-			
	A6	US-			
	A7	US-			
	A8	US-			
	A9	US-			
	A10	US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document Country Code ² Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	B1					
	B2					
	B3					
	B4					
	B5					
	B6					

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C1	SHICHIJO ET AL., "The effects of anti-asthma drugs on mediator release from cultured human mast cells," <i>Clinical and Experimental Allergy</i> 28(10):1228-1236 (1998).	
	C2	ROSSI ET AL., "Development and utilization of cultured human mast cells for high throughput small molecule drug discovery," <i>Molecular Biology of the Cell</i> 12:512A-513A (2001).	
	C3	IGARISHI ET AL., "Characteristics of histamine release from cultured human mast cells," <i>Clinical and Experimental Allergy</i> 26(5):597-602 (1996).	
	C4	HOFFMAN ET AL., "Determination of the allergenic activity of birch pollen and apple prick test solutions by measurement of beta-hexosaminidase release from RBL-2H3 cells. Comparison with classical methods in allergen standardization," <i>Allergy</i> 54(5):446-454 (1999).	
	C5	IKAWATI ET AL., "Screening of several Indonesian medicinal plants for their inhibitory effect on histamine release from RBL-2H3 cells," <i>Journal of Ethnopharmacology</i> 75(2-3):249-256 (2001).	
	C6		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2